Effects Of Rimonabant On Cardiometabolic Risk Profile Include Loss Of Visceral Fat And Mobilization Of Liver Fat
May 15th 2008Drug InformationCholesterol
At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
